STAAR Surgical Company (NASDAQ: STAA) announced preliminary net sales for its second quarter ended July 3, 2026, with revenue expected to exceed $90 million, compared to $44.3 million in the same quarter of 2025.

According to the company's press release, growth was led by sequential gains in China, solid performance across the broader Asia-Pacific region, and double-digit percentage growth in the Americas. In the EMEA region, net sales declined by a low single-digit percentage, which the company attributed to ongoing turmoil in the Middle East. Excluding the Middle East, EMEA recorded double-digit percentage growth.

The company noted that the prior-year quarter was affected by minimal shipments of EVO ICL lenses to China while distributors worked through excess inventory. As of the end of the second quarter of 2026, distributor inventory appears to be within the company's targeted range.

Warren Foust, Co-CEO, President and Chief Operating Officer, said the quarter presented "meaningful operational challenges" related to an ERP system implementation, adding that the company remains "focused on resolving the remaining system issues in the third quarter."

STAAR cautioned that geopolitical and macroeconomic headwinds in the Middle East and certain parts of EMEA and Asia-Pacific continued to weigh on sales in those areas. The company warned that if these conditions persist or worsen, or if challenges spread to additional regions, future results could be negatively affected.

The financial data is unaudited and subject to adjustment. STAAR expects to release full second-quarter results on August 12, 2026.